Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).
Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).
The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.
Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.
Previously: Momenta Pharmaceuticals EPS misses by $0.73, misses on revenue (Aug. 2)
Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).
Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).
The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.
Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.
Previously: Momenta Pharmaceuticals EPS misses by $0.73, misses on revenue (Aug. 2)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.